US asks Bharat Bio partner Ocugen to halt Covaxin trials

"The company was informed by the USFDA that the agency placed its phase 2/3 immuno-bridging and broadening study for Covaxin (BBV152), OCU-002, on clinical hold," Ocugen said in a statement.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/xicETgj
via IFTTT